image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 9 days, don't miss out!

Somero

September 2022

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SOM
  • Price:
  • 425p
Somero has announced that helped by strong order backlogs full year results will be in line with expectations and it expects to make revenues of US$138.8m, EBITDA of US$47.7m, and year-end cash of approximately US$39.9m, matching last year’s elevated levels. New products contributed meaningfully to H1 sales and the company is making good progress identifying opportunities to penetrate untapped market segments, while also developing new solutions for customers. It’s also on track to complete its expansion at Houghton, Michigan by the end of Q3.While rising interest rates in the US add some uncertainty to end market demand the shares look way over-sold on a prospective PE of 8.1 (eps forecast: 62.8 cents (52.6p). I am a buyer. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author